Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
33.96
+0.26 (+0.77%)
Official Closing Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
35
36
Next >
June 2023 Stock Considerations
June 07, 2023
With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases.
Via
Talk Markets
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
June 06, 2023
Benzinga
Via
Benzinga
FDA Prioritizes GSK's Breakthrough Drug Jemperli for Endometrial Cancer Treatment, a First in Decades
June 06, 2023
Via
Benzinga
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
June 01, 2023
From
GSK plc
Via
Business Wire
Peering Into GSK's Recent Short Interest
May 19, 2023
Via
Benzinga
GSK Stock: A Value Trap or a Hidden Gem?
April 27, 2023
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
May 25, 2023
Via
Benzinga
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
May 19, 2023
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the
Via
Benzinga
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
From
BELLUS Health Inc.
Via
Business Wire
Could Latecomer Moderna Match Big Pharma Rivals in RSV?
May 16, 2023
RSV is a key part of Moderna's respiratory vaccine business.
Via
The Motley Fool
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
May 15, 2023
The U.S.
Via
Benzinga
3 Personalized Medicine Stocks to Buy for Long-Time Returns
May 15, 2023
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out.
Via
InvestorPlace
GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo?
May 12, 2023
GSK plc (NYSE: GSK) presented preliminary results from the phase 3 trial of imm
Via
Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
May 12, 2023
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have
Via
Benzinga
GSK Trims Stake On Consumer Business Spin Off, Raises £804M
May 12, 2023
GSK Plc (NYSE: GSK) sold 240 mi
Via
Benzinga
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
May 12, 2023
The monoclonal antibody shot significantly reduced the risk of hospitalization in babies.
Via
Investor's Business Daily
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
May 11, 2023
RSV could be the next big battleground for big pharma -- but it could soon become crowded.
Via
The Motley Fool
Dividend Income Update April 2023
May 11, 2023
With May already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income their portfolios generated.
Via
Talk Markets
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
May 08, 2023
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug
Via
MarketBeat
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
May 08, 2023
The World Health Organization ended the global emergency
Via
Benzinga
GSK: Add This Cheap Chip Play To Your Portfolio
May 06, 2023
GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%.
Via
Talk Markets
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
May 04, 2023
From
HKTDC
Via
ACN Newswire
A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market
May 03, 2023
The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in...
Via
Benzinga
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
May 03, 2023
From
GSK plc
Via
Business Wire
GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line
May 03, 2023
GSK won FDA approval for the first-ever RSV vaccine for older adults.
Via
Investor's Business Daily
KVUE Stock: Should You Buy Into the Kenvue IPO?
May 03, 2023
KVUE stock will be a dividend stock with an initial yield of 3.5%, with slow growth and lower margins than JNJ's drug business.
Via
InvestorPlace
Pharma Giant Pfizer To Start Selling Haleon Stake Within Months, CFO Says
May 03, 2023
Pfizer Inc (NYSE: PFE) is reportedly looking to start selling its stake in Haleon plc (NYSE: HLN).
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
April 28, 2023
Microsoft, Meta, Cloudflare and Crocs were among the many big movers.
Via
Investor's Business Daily
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.